Skip to main content
Caplight Logo









Hopstem Biotechnology

Hopstem Biotechnology

Private
HangzhouHealthcare & Life Scienceshttp://hopstem.com/

Last Round

Series C

Aug 10, 2026

Total Funding Raised

$55.5M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Hopstem Biotechnology is a biotechnology company that develops induced pluripotent stem cell (iPSC)-derived therapies for central nervous system disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Data as a Service

AI Layer

Non-AI

Keywords

iPSCinduced pluripotent stem cellstem cell therapycell therapyregenerative medicineneural progenitor cellallogeneic cell therapyneurological disordersGMP manufacturingdrug discovery servicesstroke treatmentneurotoxicity testingoff-the-shelf therapycell line licensingbiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hopstem Biotechnology Comparables

Compare Hopstem Biotechnology with similar companies based on industry and business-model similarity.

Hopstem Biotechnology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
XellSmart
84%
iRegene Therapeutics
81%
Allife Medicine
80%

Hopstem Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CAug 10, 2026
Series BOct 31, 2021
Series A ExtensionMay 28, 2021
Series A ExtensionDec 1, 2020
Series ADec 24, 2018

Key People

Founding team and executive leadership

D.Phil. Chia-Hua Maggie Ho

Chief Operating Officer

Executive Team

Hopstem Biotechnology Investors

Notable investors and investment history

Hopstem Biotechnology investors
InvestorRounds
Cybernaut Investment GroupAngel
Longmen CapitalSeries A Extension
Hillhouse InvestmentSeries B
YuanBio Venture CapitalSeries B, Angel, Series A Extension
Daoyuan CapitalSeries A
Tasly CapitalSeries C
Empower InvestmentAngel

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 414% MoM.

  • Aug 10, 2026

    Raised $28M with Tasly Capital participating.

Hopstem Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hopstem Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hopstem Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range10
Year Founded2017
Last FundingAug 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?